Totally thought it was him too. Who would liquidate at that price like that? 80s by Friday?
Gap at the open. I am waiting on a positive hit piece from SA tomorrow
Consolidated revenues for 2013 were $434.4 million compared to $401.4 million in 2012. Copper and gold sales contributed $14.3 million of additional revenue in 2013. Molybdenum sales volumes were 36.5 million pounds in 2013 compared to 28.7 million pounds in 2012. Our average realized sales price for molybdenum in 2013 was $10.97 per pound compared to $13.48 per pound in 2012.
Consolidated operating loss for 2013 was $175.3 million compared to an operating loss of $607.7 million for 2012. Consolidated operating loss for 2013 was impacted by a pre-tax write down of the fixed assets and materials and supplies inventory at the Thompson Creek Mine ("TC Mine") and Endako Mine of $194.9 million and lower-of-cost-or-market product inventory write downs of $51.0 million. Consolidated operating loss for 2012 was impacted by a fixed asset pre-tax write down at Endako Mine of $530.5 million and lower-of-cost-or-market product inventory write downs of $73.8 million.
DENVER, CO--(Marketwired - Feb 20, 2014) - Thompson Creek Metals Company Inc. (NYSE: TC) (TSX: TCM) (the "Company" or "Thompson Creek"), a diversified North American mining company, announced today that its Mt. Milligan copper and gold mine achieved commercial production on February 18, 2014, which the Company defines as operation of the mill for a period of 30 days at 60% or more of design capacity mill throughput, equivalent to 36,000 tonnes per day.
"Achieving commercial production is a significant milestone for the Company," said Jacques Perron, Chief Executive Officer of Thompson Creek. "We are seeing steady improvements on a daily basis and remain focused on optimizing operating performance at the mine and mill to achieve full design capacity," added Mr. Perron.
The Company also announced financial results for the three months and year ended December 31, 2013, prepared in accordance with United States generally accepted accounting principles ("US GAAP"). All dollar amounts are in United States ("US") dollars unless otherwise indicated.
Who knows. Might be cover for them to get a ten cent break or something. Even with the massive market sell off today this stock held to a small decline for the day overall. Sign of strength to me. I have a gut feeling earnings are going to be good honestly. I like gut feelings lol
Any ideas? Is a bad CC being baked in at this point? With the short interest here I assumed most would cover half of their position going into earnings. This sell off here has me baffled. Thoughts?
3rd Quarter Earnings are going to set the record straight. Look for the Mayweather vs Pacquiao fight. That fight will be watched at BLWD. Last Mayweather fight the earnings were great and it ran to 150.... I like this stock with an major fight event with Mayweather. GL
Haha. I wish! Can't deny the results were solid. I am actually just a loser who posts to message boards without compensation
TotipotentRX/ThermoGenesis recently announced landmark results from their Critical Limb Ischemia Trial. Results were so spectacular they caused shares to rise sharply on 50 million shares just in the first two days. That was over 3 times the 16.7 million total outstanding company shares and more than 300 times the average daily volume of 80,000 shares for the previous 90 days.
The trial was an open label study of 17 patients whose condition was so advanced there was no option for treatment. All 17 patients were scheduled for limb amputation. The patients were treated with an autologous bone marrow procedure using proprietary procedures and equipment. The procedure was performed at the bedside and took less than 60 minutes.
Highlights from CLI trial
Before treatment, 100% of patients required amputation
12 months after treatment, 82.4% of patients had no amputation
Pain level before treatment on a scale of 0 to 10 was severe at 7.8
Pain level 12 months after treatment was almost non existent at0.2
6-minute walking distance before treatment was 14.5 meters
6-minute walking distance 12 months after treatment was 157meters
Before treatment, 11 patients had gangrene with or without ulceration
12 months after treatment 0 patients had gangrene or ulceration
This stock “this week” with the news was a victim of the market overall. Everyone is freaking out (because most traders have zero patience or discipline) for reasons we all knew existed but ignored due to QE. I think long term we see pops on continued good news from FDA results. But as I have learned nothing is a sure thing. Good luck on you position whether long or short.